KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Equity Income (2017 - 2025)

Historic Equity Income for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $28.8 million.

  • Takeda Pharmaceutical's Equity Income rose 17352.94% to $28.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $50.6 million, marking a year-over-year decrease of 2759.26%. This contributed to the annual value of -$26.2 million for FY2025, which is 15829.95% down from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Equity Income stood at $28.8 million, which was up 17352.94% from $10.2 million recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Equity Income peaked at $76.4 million during Q1 2021, and registered a low of -$28.8 million during Q3 2021.
  • Moreover, its 5-year median value for Equity Income was -$214134.2 (2025), whereas its average is $5.7 million.
  • In the last 5 years, Takeda Pharmaceutical's Equity Income crashed by 47084.54% in 2021 and then surged by 76800.08% in 2024.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Equity Income stood at -$15.2 million in 2021, then increased by 17.82% to -$12.5 million in 2022, then dropped by 24.41% to -$15.6 million in 2023, then surged by 167.64% to $10.5 million in 2024, then soared by 173.53% to $28.8 million in 2025.
  • Its last three reported values are $28.8 million in Q4 2025, $10.2 million for Q3 2025, and $9.0 million during Q2 2025.